idebenone has been researched along with Aging in 8 studies
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report that α-tocotrienol quinone (ATQ3) is a metabolite of α-tocotrienol, and that ATQ3 is a potent cellular protectant against oxidative stress and aging." | 7.77 | α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging. ( Amagata, A; Barnes, A; Enns, GM; Hinman, A; Jankowski, O; Kheifets, V; Komatsuzaki, R; Lee, E; Miller, G; Mollard, P; Murase, K; Sadun, AA; Shrader, WD; Thoolen, M; Wesson, K, 2011) |
| "We report that α-tocotrienol quinone (ATQ3) is a metabolite of α-tocotrienol, and that ATQ3 is a potent cellular protectant against oxidative stress and aging." | 3.77 | α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging. ( Amagata, A; Barnes, A; Enns, GM; Hinman, A; Jankowski, O; Kheifets, V; Komatsuzaki, R; Lee, E; Miller, G; Mollard, P; Murase, K; Sadun, AA; Shrader, WD; Thoolen, M; Wesson, K, 2011) |
| "Idebenone is a benzoquinone compound which has been investigated in elderly patients with dementia." | 2.39 | Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. ( Benefield, P; Gillis, JC; McTavish, D, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shrader, WD | 1 |
| Amagata, A | 1 |
| Barnes, A | 1 |
| Enns, GM | 1 |
| Hinman, A | 1 |
| Jankowski, O | 1 |
| Kheifets, V | 1 |
| Komatsuzaki, R | 1 |
| Lee, E | 1 |
| Mollard, P | 1 |
| Murase, K | 1 |
| Sadun, AA | 1 |
| Thoolen, M | 1 |
| Wesson, K | 1 |
| Miller, G | 1 |
| García-Giménez, JL | 1 |
| Gimeno, A | 1 |
| Gonzalez-Cabo, P | 1 |
| Dasí, F | 1 |
| Bolinches-Amorós, A | 1 |
| Mollá, B | 1 |
| Palau, F | 1 |
| Pallardó, FV | 1 |
| Nabeshima, T | 2 |
| Nitta, A | 2 |
| Fuji, K | 1 |
| Kameyama, T | 1 |
| Hasegawa, T | 2 |
| Gillis, JC | 1 |
| Benefield, P | 1 |
| McTavish, D | 1 |
| Pelleymounter, MA | 1 |
| Cullen, MJ | 1 |
| Curti, D | 1 |
| Izzo, E | 1 |
| Brambilla, L | 1 |
| Facchetti, G | 1 |
| Sangiovanni, G | 1 |
| Brambilla, G | 1 |
| Kamei, C | 1 |
| Tsujimoto, S | 1 |
| Tasaka, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Therapeutic Trial of EPI -743 In Patients With Disorders of Energy Utilization or Oxidation-Reduction[NCT01642056] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2012-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"NPMDS is a semi-quantitative clinical rating scale that evaluates the progression of mitochondrial disease in pediatric patients.~The NPMDS scale provides an assessment of the progression of mitochondrial disease. Scores from Parts I-III are added to get a value between 0 and 130, with higher scores representing more severe disease." (NCT01642056)
Timeframe: 14 months
| Intervention | Units on a scale (Mean) |
|---|---|
| EPI-743, Then Placebo | 26 |
| Placebo, Then EPI-743 | 15.8 |
"NPMDS is a semi-quantitative clinical rating scale that evaluates the progression of mitochondrial disease in pediatric patients.~The NPMDS scale provides an assessment of the progression of mitochondrial disease. Scores from Parts I-III are added to get a value between 0 and 130, with higher scores representing more severe disease." (NCT01642056)
Timeframe: 6 months
| Intervention | Units on a scale (Mean) |
|---|---|
| EPI-743, Then Placebo | 27.1 |
| Placebo, Then EPI-743 | 20.2 |
"NPMDS is a semi-quantitative clinical rating scale that evaluates the progression of mitochondrial disease in pediatric patients.~The NPMDS scale provides an assessment of the progression of mitochondrial disease. Scores from Parts I-III are added to get a value between 0 and 130, with higher scores representing more severe disease." (NCT01642056)
Timeframe: Baseline - Day 0
| Intervention | Units on a scale (Mean) |
|---|---|
| EPI-743, Then Placebo | 23.9 |
| Placebo, Then EPI-743 | 20.4 |
"NPMDS is a semi-quantitative clinical rating scale that evaluates the progression of mitochondrial disease in pediatric patients.~The NPMDS scale provides an assessment of the progression of mitochondrial disease. Scores from Parts I-III are added to get a value between 0 and 130, with higher scores representing more severe disease." (NCT01642056)
Timeframe: 8 month - Post washout
| Intervention | Units on a scale (Mean) |
|---|---|
| EPI-743, Then Placebo | 27.1 |
| Placebo, Then EPI-743 | 18.3 |
1 review available for idebenone and Aging
| Article | Year |
|---|---|
Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.
Topics: Administration, Oral; Aging; Benzoquinones; Cognition Disorders; Drug Administration Schedule; Human | 1994 |
7 other studies available for idebenone and Aging
| Article | Year |
|---|---|
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging.
Topics: Aging; Animals; Antioxidants; Benzoquinones; Cells, Cultured; Dogs; Dose-Response Relationship, Drug | 2011 |
Differential expression of PGC-1α and metabolic sensors suggest age-dependent induction of mitochondrial biogenesis in Friedreich ataxia fibroblasts.
Topics: Adenosine Triphosphate; Adolescent; Adult; Aging; Alleles; AMP-Activated Protein Kinases; Antioxidan | 2011 |
Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats.
Topics: Administration, Oral; Aging; Analysis of Variance; Animals; Benzoquinones; Brain; Choline O-Acetyltr | 1994 |
Effects of idebenone on information processing in aged Long-Evans rats.
Topics: Aging; Animals; Anxiety; Attention; Benzoquinones; Cognition; Environment; Habituation, Psychophysio | 1993 |
Oral administration of idebenone, a stimulator of NGF synthesis, recovers reduced NGF content in aged rat brain.
Topics: Administration, Oral; Aging; Animals; Benzoquinones; Brain; Choline O-Acetyltransferase; Frontal Lob | 1993 |
Effect of a ubiquinone-like molecule on oxidative energy metabolism in rat cortical synaptosomes at different ages.
Topics: Adenosine Triphosphate; Aging; Animals; Benzoquinones; Cerebral Cortex; Energy Metabolism; Enzyme Ac | 1995 |
Effects of cholinergic drugs and cerebral metabolic activators on memory impairment in old rats.
Topics: Acetylcholine; Aging; Animals; Benzoquinones; Brain; Central Nervous System Agents; gamma-Aminobutyr | 1990 |